Daily Updates on Generic Entry, Litigation, Biosimilars, and more …
Want insights into the biggest revenue-changing events?
Billions of dollars in sales can evaporate overnight as drug patents expire and competitors enter the market.
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
Safety and Tolerance of Zidovudine With Probenecid and the Effect of Probenecid on Zidovudine Pharmacokinetics Over Four Weeks
Completed
National Institute of Allergy and Infectious Diseases (NIAID)
N/A
1969-12-31
To evaluate the interaction of probenecid with zidovudine (AZT). Because AZT is eliminated
quickly from the body, it must be taken frequently. A previous study showed that probenecid
slowed the elimination of AZT without side effects, but that study lasted only 5 days. This
study is to see whether this effect continues for 1 month and whether the continuation of
probenecid and AZT is free of side effects over 1 month.
Influence of Probenecid and Quinine on the Pharmacokinetics of Azidothymidine
Completed
National Institute of Allergy and Infectious Diseases (NIAID)
N/A
1969-12-31
Part I studies the effect of quinine on how zidovudine (AZT) is used by the body and
eliminated through the kidneys in HIV infected patients. Part II studies the effect of
probenecid and quinine on the same aspects.
Because AZT leaves the bloodstream quickly, patients must take the drug frequently to keep
adequate amounts in their bodies. Probenecid and quinine may slow down the rate at which AZT
leaves the body. Therefore, taking these drugs along with AZT may reduce the amount of AZT
needed for treatment.
To evaluate short-term and long-term safety and efficacy of intravenous cidofovir (HPMPC)
for treatment of small peripheral cytomegalovirus (CMV) retinitis lesions. To provide data
on the relative safety and efficacy of 2 doses of HPMPC as maintenance regimens.
National Institute of Allergy and Infectious Diseases (NIAID)
N/A
1969-12-31
To evaluate short-term and long-term safety and efficacy of intravenous cidofovir (HPMPC)
for treatment of small peripheral cytomegalovirus (CMV) retinitis lesions. To provide data
on the relative safety and efficacy of 2 doses of HPMPC as maintenance regimens.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
